Drug-eluting balloon: is it useful?

Sidhi Laksono1,2*, Budhi Setianto3 and Steven Philip Surya4

Abstract

Background: Coronary artery disease is one of the major issues in the medical world around the globe. The prevalence tends to increase. The use of coronary intervention is one of the ways often used in the management of coronary artery disease due to its satisfying result from earlier studies. Nowadays, there are several different techniques in coronary intervention: balloon vs stent.

Main body: The stent-based vascular interventions are increasingly being used over balloon-based coronary intervention. However, revascularization intervention using stent often have undesirable long-term effects compared to balloon. Besides, stent-based interventions are also considered more expensive, use more complicated techniques, and use more drug regimens. On the other hand, percutaneous coronary intervention techniques using balloons coated by anti-proliferation drugs have begun to be glimpsed by many interventionists. Studies have found many benefits that cannot be given by stent-based intervention therapy.

Conclusions: Angioplasty using percutaneous coronary intervention techniques reveals satisfying result compared to conservative medical treatment. The indication and technique of percutaneous coronary intervention is still evolving until now. Currently, percutaneous coronary intervention using stent, either bare-metal stent or drug-eluting stent, is preferred by interventionist. Nevertheless, recent clinical trial favors the using of drug-eluting balloon for percutaneous coronary intervention in terms of both clinical outcome and complication in several scenarios.

Keywords: Coronary artery disease, Coronary intervention, Stent, Drug-coated balloon

Background

Since the time when the first-time angioplasty for vascular intervention was introduced, the need of angioplasty for management of artery diseases was increasing. In the increase of angioplasty procedure parallel with its early promising study for the cardiac disease patients, only 5 undesirable events of cardiac death from 169 patients underwent cardiac catheterization after 10 years [1]. The first large trial conducted by the National Heart, Lung, and Blood Institute (NHLBI) which involved 2500 patients with percutaneous transluminal coronary angioplasty (PCTA) showed an unquestionable result from multiple indicators like increase of immediate success rate, decrease in non-fatal myocardial infraction, and emergency coronary artery bypass graft surgery [1]. Stent-based techniques are more common in practice recently, but there are still some limitations to these techniques [2, 3]. Likewise, long-term benefit of the stent-based PCI over drug-eluting balloon techniques is still questionable [2].

Main body

Indication

Several previous trial studies showed that angioplasty has greater advantages for relieving symptoms in stable coronary artery disease patients with the no-or-mild symptoms group compared to other medical therapies [4, 5]. However, a randomized trial study discovered no significant difference in cardiac death event, myocardial infraction, and stroke from PCI therapy compared to...
other optimal medical therapies (OMT) [6]. The decision to undergo PCI for stable angina remains unclear, and it depends on patient-doctor expectations.

Conversely, angioplasty for patient with non-ST elevation myocardial infarct (NSTEMI) should be stratified to the high-risk vs low-risk groups first [4]. The high-risk group was defined by dynamic ST segment changes, elevated troponin-I/troponin-T/CK-MB levels, GRACE score, and other secondary criteria. An obvious benefit of PCI for NSTEMI patients (cardiac death event, myocardial infarction, and refractory angina) was found in patients with the high-risk group [4, 7]. Previous studies showed that immediate intervention has no significant advantages and tends to give more harm in clinically unstable patients [8–10].

More specific indications for PCI were patients with acute coronary syndrome (ACS) and evidence of persistent ST segment elevation (STEMI) or presumed new bundle-branch block. However, primary PCI in STEMI required an interventional cardiologist, short respond time, and well-trained support staff. Even worse, a study from Egypt showed that all patients who were diagnosed with STEMI came into the emergency department at the end of the golden period time or after the golden period time [4]. Another study has demonstrated that pharmacology therapy preceding PCI could prolong the golden period time [11]. Notwithstanding many argumentations about the cutoff of the extended period, the longest time PCI delay was 180 min [12].

Pathophysiology of restenosis
Angiographically, restenosis defines an obstruction of >50% of the luminal diameter at the site of intervention segment (or within the stent) or within the adjacent 5 mm from the intervention segment after PCI procedure (Fig. 1) [13–15]. It is caused by an endothelial pathologic response to the injury. The harmful vascular remodeling and neointimal proliferation of vascular smooth muscle cells and/or new occurring atherosclerotic process is called “neoatherosclerosis.” Restenosis usually is managed with immediate reintervention either by coronary artery bypass graft (CABG) or another PCI. Some cases found restenosis accidentally while performing coronary angiography in asymptomatic patients [15]. Many studies report that restenosis (Fig. 1) incidences occur in more than 30–40% population after PCI procedure [14–16].

There are numerous ways to diagnose luminal obstruction after PCI, such as comparing minimal luminal diameter (MLD) post-intervention with follow-up diameter, intravascular ultrasound (IVUS), and noninvasive technique like optical coherence tomography (OCT), multidetector computer tomography (MDCT), and fractional flow reserve (FFR) [14]. Noninvasive imaging modality was more preferred by the patient, but its role in detecting restenosis is still limited [17].

A previous retrospective study with 3448 patients found that independent risk variables for restenosis are history of smoking, diabetes, ostial lesion, bifurcation lesion, post-procedural MLD, reference diameter (less than 3.25 mm), and lesion length (>30 mm) [18]. Other studies concluded that restenosis depends on several predictors such as clinical, procedural, and angiographic [16, 19].

Right after inflating the balloon, the entire thickness of the artery will stretch. Tunica media and adventitia layer might get injured by the balloon’s expansion, and the healing process occurs following the vascular injury. The healing process consists of several processes such as

![Fig. 1 Focal ISR classification according to angiographic classification. IA Articulation or gap. IB Margin. IC Unifocal. ID Multifocal](image-url)
platelet aggregation, inflammatory cell infiltration, release of growth factors, medial smooth muscle cell (SMC) modulation and proliferation, proteoglycan deposition, and extracellular matrix (ECM) remodeling [14]. The satisfying end point of the healing process is reendothelialization without significant diameter narrowing.

In pathogenic conditions, neointimal hyperplasia as a negative vascular remodeling process occurs and it causes vascular narrowing. Nitric oxide releases right after stress injury to the endothelial wall. In this situation, cells also release some cytokines like platelet-derived growth factor (PDGF) and transforming growth factor-β (TGF-β). Those cytokines promote migration and proliferation of vascular smooth muscle cells (VSMC) [14]. Besides cellular inflammatory response (such as infiltration of macrophage, T cell, B cell, and eosinophil), patient’s specific risk factor (clinical and genetic) and procedure-related factor also contribute to restenosis event [20]. There are some clinical conditions related to restenosis event such as diabetes mellitus, smoking status, hypertension, myocardial infarction, previous PCI, and female gender [16, 20].

Drug-eluting balloon (DEB) VS stent-based PCI

Historically, the use of stent implantation aims to deal with vascular dissection [21]. Nonetheless, long-term benefits of stent implantation for coronary artery disease are still debatable [22]. On the other hand, DEB has been proven to elude the late complication of the coronary restenosis as well as simplifying PCI procedure. Two studies from the Belgian Netherland Stent Study (BENESTENT) and Stent Restenosis Study (STRESS) conclude only 5.1% and 6.9%, respectively, balloon-based angioplasty patients need to undergo crossing over to stent technique due to acute vessel complications [21]. In the stent-based PCI era, there are several indications for using balloon-based angioplasty such as stent delivery failure/expected to be difficult due to calcification and intervention for in-stent restenosis/stent thrombosis. Instead, head-to-head comparison between balloon-based angioplasty and stent-based angioplasty in small vessel displays DEB is not inferior compared to the stent-based PCI in terms of re-stenosis’ rate [22]. Furthermore, intracoronary stent restenosis (ISR) and stent thrombosis remain the major problems even with drug-eluting stent (DES) techniques [21, 23, 24]. The ISR incidence is still as high as 12% after 6 months follow-up even with the new generation of the eluting stent [25].

The DEB is an angioplasty procedure using semi-compliant balloons layered with a cytotoxic chemotherapeutic drug. It can spread the drug more equivalently to the endothelial lining compared to the DES technique [26]. One study using a sirolimus-coated balloon indicates low major adverse cardiac event (MACE) rate (5.38%) within 12 months follow-up [21]. A single-center registry study (DEB = 601 patients and DES = 1594) reveals that balloon angioplasty is more beneficial to use in patients with more than three vascular diseases and smaller vessels and finds that the stent-based group favors stent/lesion thrombosis and targets vessel re-infraction after >1 year follow-up [27]. In other advantages regarding medication therapy, many cardiologists are only using a single antiplatelet for 1 month after DEB procedure compared to stent technique that requires dual antiplatelet therapy for around 1 year [21, 25, 27].

Other studies (25 patients) also discovered potential benefits of DEB that could let the blood vessel to reclaim its initial vasomotion ability compared to the stent-based PCI [28]. During blood vessel remodeling after angioplasty, the metal stent could be in malposition [29]. A long-term study comparing the MACE rate from DEB only with paclitaxel-coated balloon and DEB + bare metal stent (BMS) in a small coronary artery concludes low MACE rate in DEB-only angioplasty (6.1% vs 37.5%) after a 3-year follow-up study [30]. A multi-center international registry also favors paclitaxel-coated balloon in small vessels with only a small number of undesirable events (3.6% target lesion revascularization/TLR, 0.6% had vessel thrombosis in non-target lesions, no cardiac death report or coronary artery bypass graft surgery) [31]. A long-term longitudinal study up to 9 years follow-up shows that balloon angioplasty is more superior compared to BMS and DES in terms of target vessel re-infraction caused by restenosis and also lesion thrombosis [21].

Many randomized controlled trials support evidence that DEB is a better option for lesions in small coronary vessel bifurcation lesions, long lesions, and pediatric interventions [25]. The BMS and DES group are dealing with some problems such as metallic cage which could delay reendothelialization, malposition, under-expansion, and chronic inflammation that may contribute to restenosis [21]. Many of the preceding studies display promising results of the DEB exclusively in small coronary arteries, but recent international consensus emphasize the DEB even in large vessel disease and high bleeding risk patient [31]. The DEBUT trial (de-novo coronary artery lesions in patients with high bleeding risk) includes a larger diameter of coronary arteries lesions (2.5–4 mm) patient in the trial and only 1% MACE incidence at 9 months follow-up compared with 14% in the bare metal stent group (risk ratio 0.07 [95% CI 0.01 to 0.52]) [32]. In another single-center study in which 60% of the patients with lesions in more than 3 mm coronary vessels and de novo lesions including large proximal coronary arteries are managed by DEB, it shows a 7.1% MACE
rate in stable coronary artery diseases and 12% in acute coronary syndrome [33].

Limitation of DEB
Despite all the benefits of DEB, still, it has some limitations in specific scenarios. A recent study comparing DEB and DES for management of ISR in DES (1377 lesions) and BMS (722 lesions) concludes that DEB for DES-IR treatment have a tendency of higher risk of ischemia-driven TLR (HR 1.67; 95% CI 1.21 to 2.31) and target vessel revascularization (HR 1.39; 95% CI 1.05 to 1.84) compared to DES in 3 years follow-up [34]. A randomized clinical trials with 1177 patients and shorter end point (1 year follow-up) shows DEB associated with higher risk of MACE, target vessel revascularization, TLR, binary stenosis, and more diameter stenosis % in the DES-ISR group compared to the new generation DES [35]. The New Tokyo Registry consists of as much as 304 consecutive patients (333 lesions) comparing DEB in the management ISR based on the number of metallic layers [36]. The study consists of three groups: 1 stent layer (166 patient), 2 stent layers (87 patient), and 3 and more stent layers (51 patients). It suggests that 3 and more stent layers is an independent predictor for MACE compared to 1 stent layer (HR 2.21; 95% CI 1.12–4.36). Unfortunately, the study about DEB and DES-ISR is limited. A multi-center study from Korea proves that optimizing procedure-related factors during DEB for management of DES-ISR could be the answer [37]. Optimize preparation includes 1:1 balloon and vascular diameter, and longer DEB inflation time more than 60 s could bring a magnificent result in a 1-year follow-up.

Regarding dual antiplatelet therapy (DAPT) in DEB patients, the European Society of Cardiology (ESC) recommends 3 months in using DAPT [38]. However, a study which compares about superiority combination DEB and DAPT and other modalities is not clearly been done before. The ABSORB III study compares 1322 patients with bioresorbable vascular scaffold (BVS) and DES, from a 1-year study BVS non inferior than DES. However, a 3 years follow-up shows BVS turn in higher TLF incidence than DES [39]. A study comparing head-to-head between BVS and DEB is limited.

Transplant coronary artery disease (TCAD) is also one of the major issues faced by both the cardiac interventionist and cardiac surgeon [40]. The TCAD incidence is quite high, as much as 30–50% within 5 years [41]. However, there is no study about TCAD management with DEB technique. Everolimus as immunosuppression therapy in heart transplant could give benefits in long-term TCAD incidence, but cannot eliminate it [42]. The current understanding about TCAD is not only by immunologic respond but also non-immunologic respond [43]. Still, recurrent TCAD becomes frustrating event in heart transplant, and palliative PCI might be the best management which could be done right now.

There are three major parts of stent: a metal scaffold, active pharmacological agent, and drug’s carrier. Latest generation of stents has thinner struts, and those models correlate with less restenosis incident [44]. The Triple Assessment of Neointima Stent F0rmation to ReAbsorbable polyMer With Optical Coherence Tomography (TRANSFORM-OCT) analyzed a multivessel disease which compares new generation (thinner struts) BMS and DES [45]. Both newer generation of DES and BMS shows magnificent results in terms of neatherosclerosis at 18 months end point. Besides, in terms of thick-struts, polymer coating technology surface (smooth surface, microporous, microporous, nanoporous, and drug-filled stents) also helps to increase drug delivery and decrease ISR problem [46]. A recent update about biotechnology of stent’s scaffold might diminish DEB function in the future; even third generation of DES could overcome ISR in diabetic patients which has high rate of ISR [47].

Conclusion
PCI was one of the revolutionary technologies in coronary artery diseases. The indications for PCI technologies are evolving parallel with new studies which show the beneficial use of PCI. Nowadays, stent-based techniques are the most common procedures for patients with de novo artery coronary disease. However, not all cases could be done by stent-based PCI. The DEB techniques have a considerable potential on that case. Currently, a growing clinical indication for de novo coronary artery lesion is that it can be managed by DEB-only PCI since it is superior in long-term effect compared to either BMS or DES. The restenosis rate of the DEB is lower compared to stent-based PCI. Additionally, DEB-only PCI could offer other benefits in terms of cost, implantation technique, and antiplatelet regimen. Nowadays, many studies start to use DEB-only PCI in a larger blood vessel diameter and it shows promising result. On the other hand, DEB also has some limitations especially for the management of DES-ISR. Unfortunately, a head-to-head study of DEB and other methods is limited and needs further investigation.

Abbreviations
CAD: Coronary artery disease; PCI: Percutaneous coronary intervention; NHLBI: National Heart, Lung, and Blood Institute; PTCA: Percutaneous transluminal coronary angioplasty; OMT: Optimal medical therapy; NSTE MI: Non-ST elevation myocardial infarct; STEMI: ST elevation myocardial infarct; CK-MB: Creatinine kinase myocardial band; GRACE Score: The Global Registry of Acute Coronary Events Score; ACS: Acute coronary syndrome; CABG: Coronary artery bypass graft; MLD: Minimal luminal diameter; IVUS: Intravascular ultrasound; OCT: Optical coherence tomography; MDCT: Multidetector computer tomography; SMC: Smooth muscle cell; ECM: Extracellular matrix; PDGF: Platelet-derived growth factor; TGF-
B: Transforming growth factor-β; VSMC: Vascular smooth muscle cells; BENESTENT: Belgian Netherlands Stent Study; STRESS: Stent Restenosis Study; ISR: Intracoronary stent restenosis; DES: Drug-eluting stent; MACE: Major adverse cardiac event; BMS: Bare metal stent; DEBUT trial: De-novo coronary artery lesions in patients with high bleeding risk

Acknowledgements

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Authors’ contributions

All authors have read and approved the manuscript. SL and BS performed the initial concept, revision, and final approval. SPS performed the draft manuscript.

Funding

There has been no funding for this study.

Availability of data and materials

Not applicable

Ethics approval and consent to participate

Not applicable; it is a review article; no ethical committee approval is required.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Author details

1Cardiac Catheterization Laboratory, Department of Cardiology and Vascular Medicine, RSUD Pasar Rebo, Jakarta, Indonesia. 2Faculty of Medicine, Universitas Muhammadiyah Prof. DR. Hamka, Tangerang, Indonesia. 3Department of Cardiology and Vascular Medicine of National Cardiovascular Center of Harapan Kita, Faculty of Medicine of Universitas Indonesia, Jakarta, Indonesia. 4Army Hospital Kesdam Jaya Cijantung, Jakarta, Indonesia.

Received: 28 August 2020 Accepted: 30 October 2020
Published online: 11 November 2020

References

1. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB, Loop FD et al (1998) Guideline for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (subcommittee on percutaneous transluminal coronary angioplasty). JACC. 12(2):529–545
2. Stolker JM, Kennedy KF, Lindsey JB, Marso SP, Pencina MJ, Cutlip DE et al (2010) Predicting restenosis of drug-eluting stents placed real-world clinical practice derivation and validation of a risk model from the EVENT registry. Circ Cardiovasc Interv. 3:327–334
3. Purvisn R, Korley F, Gopaul P, Kanade P, Chandra N, Shaw RE et al (2012) Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease. Circ Cardiovasc Interv. 5:476–420
4. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hammad M (2005) Guidelines for percutaneous coronary intervention the Task Force for Percutaneous Coronary Intervention of the European Society of Cardiology. Eur Heart J. 26B:804–847
5. Lamee RA, Thompson D, Dehbi HM, Thompson D, Dehbi HM, Sen S, Tang K, Davies J et al (2017) High-risk non-ST elevation myocardial infarction in the UK need for alternative models of care to reduce length of stay and admission to angiography times. Clin Med. 15(6):522–525
6. Koganti S, Rahit RD (2015) Management of high-risk non-ST elevation myocardial infarction in patients with high bleeding risk

8. Vukcevic V, Stankovic G (2017) Timing of invasive strategy in patients with non-ST-segment elevation acute coronary syndrome and effect on clinical outcomes. J Thorac Dis. 9(11):4236–4239
9. Kim MC, Jeon MH, Sim DS, Hong YJ, Kim JH, Ahn Y et al (2018) Optimal timing of percutaneous coronary intervention in patients with non-ST-segment elevation myocardial infarction complicated by acute decompensated heart failure from the Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH). Am J Cardiol. 121(11):1285–1292
10. Dehara P, Drucon G, Bodc, Cohen M, Cuisset M, Mehta SR et al (2017) Timing of angiography and outcomes in high-risk patients with non-ST-segment elevation myocardial infarction managed invasively from the TA0 trial (treatment of acute coronary syndrome with otamixaban). Circulation. 136:1895–1907
11. Helal AM, Shaheen SM, Elhammady WA, Ahmed ML, Hakim ASA, Allam LE (2018) Primary PCI versus pharmacoinvasive strategy for ST elevation myocardial infarction. Int J Cardiol Heart Vasc. 21:87–93
12. Terkelsen CJ, Christiansen EH, Sorensen JT, Kristensen SD, Lasen JF, Thuesen L et al (2009) Primary PCI as the preferred reperfusion therapy in STEMI: it is a matter of time. Heart. 95:362–369
13. Giacoppo D, Gariglio G, Aruta P, Capranzano P, Tumburino C, Capodanno D (2015) Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. BMJ 351:h3992
14. Elmore JB, Mehanr E, Parikh SA, Zidar DA (2016) Restenosis of the coronary arteries past, present, future directions. In: Parikh SA, Price MJ (eds) Interventional cardiology clinics. Elsevier, Philadelphia (PA), pp 281–294
15. Buccheri D, Piraino D, Andolina G, Cortese B (2016) Understanding and managing in-stent restenosis: a clinical data, from pathogenesis to treatment. J Thorac Dis. 8(10):E1150–E1162
16. Society for Cardiac Angiography and Intervention (2001) ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PCTA guideline) – executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). Circulation. 103:3039–3041
17. Kallirnas T, Halon DA, Lewis BS, Adawi S, Schlamsier RE, Rubinshtein R et al (2005) Diagnosis of coronary in-stent restenosis with multidetector row spiral computed tomography. J Am Coll Cardiol. 46(8):1573–1579
18. Chang BP, Hoop KP (2013) Identification of independent risk factor for stenosis following bare-metal stent implication: role of bare-metal stents in the era of drug-eluting stents. Exp Ther Med. 6(3):840–846
19. Heidland UQ, Heintzen MP, Michael CJ, Strauner BE (2001) Risk factors for restenosis after PCI: one factor or many factors? Eur Heart J. 22(11):1051–1059
20. Jukema JW, Vershuis JW, Ahmed TAN, Quax PHA (2012) Restenosis after PCI: a pathophysiological and risk factors. Nat Rev Cardiol. 9:53–62
21. Wickramarachchi UJ, Eccleshall S (2016) Drug-coated balloon-only angioplasty for native coronary disease instead of stents. Interventional Cardiology Review 11(2):110–115
22. Moriya M, Ishiwata S, Fujimoto Y, Mitani H, Yamaguchi T, Ohno M (2015) Characteristics and trends of POBA in current DES Era. Cardiovasc Interv Ther. 30(4):315–319
23. Jer AY, Shin ES (2018) Current management of in-stent restenosis. Korean Circ J. 48(5):337–349
24. Magalhaes MA, Minha S, Chen F, Torqunson R, Oma AF, Loh JP et al (2014) Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations. Circ Cardiovasc Interv. 7:768–776
25. Schaller B (2011) Opportunities and limitation of drug-coated balloons in interventional therapies. Herz. 36(3):222–239
26. Speck U, Sloibnzen N, Peters D, Schaller B (2016) How does a drug-coated balloon works? Overview of coating techniques and their impact. J Cardiovasc Surg (Torino). 57(1):3-11
27. Brodie BR, Polkarel Y, Gang A, Klsing G, Harsen C, Miks S et al (2014) Very late hazard with stenting versus balloon angioplasty for ST-elevation myocardial infarction: a 16- year single-center experience. J Interv Cardiol. 27(1):21–28
28. Tognini M, Windecker S, Coschi R, Wenausser P, Cook S, Billinger M et al (2005) Sirolimus-eluting stents associated with paradoxical coronary vasoconstriction. J Am Coll Cardiol. 46(2):231–236
29. Kleber FX, Schulz A, Waliszewski M, Hauschild T, Bohm M, Dietz U et al (2015) Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty. Clin Res Cardiol. 104(3):217–225
30. Unverdorben M, Kleber FX, Heuer H, Figulla HR, Vahlbruch C, Leschke M et al (2013) Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PECAD I study: are lesions clinically stable from 12 to 13 months? Eurointervention. 9(5):620–628

31. Zeymer U, Waliszewski M, Spiecker M, Gastmann O, Faurie B, Alidoosti M et al (2014) Prospective ‘real-world’ registry for the use of the PCB only strategy in small vessel de novo lesions. Heart. 100(4):311–316

32. Rissanen TT, Uskela S, Eranne J, Mantyla P, Olli A, Romppanen H et al (2019) Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomized, non-inferiority trial. Lancet. 394(10194):230–239

33. Uskela S, Karkkainen JM, Etanen J, Slijander A, Mantyla P, Mustonen J et al (2019) Percutaneous coronary intervention with drug-coated balloon-only strategy in stable coronary artery disease and in acute coronary syndrome: an all-comers registry study. Catheter Cardiovasc Interv. 93(5):893–900

34. Giacoppo D, Alfonso F, Xu B, Claessen BEPM, Adriaenssens T, Olsen C et al (2020) Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis. J Am Coll Cardiol. 75:2664–2678

35. Gao L, Wang YB, Jing J, Zhang M, Chen YD (2019) Drug-eluting balloons versus new generation drug-eluting stents for the management of in-stent restenosis: an updated meta-analysis of randomized studies. J Geriatr Cardiol. 16(6):448–457

36. Yabuhi H, Kawamoto H, Fujino Y, Tahara S, Horikoshi T, Tada M et al (2018) Clinical outcomes of drug-eluting balloon for in-stent restenosis based on the number of metallic layers. Circ Cardiovasc Interv. 11(8):e005935

37. Rhee TM, Lee JM, Shin ES, Hwang D, Park J, Joen KH et al (2018) Impact of optimized procedure-related factors in drug-eluting balloon angioplasty for treatment of in-stent restenosis. JACC Cardiovasc Interv. 11(10):969–978

38. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 39(3):213–240

39. Stone GW, Abizaid A, Onuma Y, Seth A, Gao R, Ornstein J et al (2017) Effect of technique on outcomes following bioresorbable vascular scaffold implantation: analysis from the ABSORB trials. J Am Coll Cardiol. 70(23):2863–2874

40. Kuroda K, Sunami H, Matsumoto Y, Nakajima S, Sato T, Seguchi O et al (2017) Percutaneous coronary intervention and coronary artery bypass grafting in heart transplant recipients with transplant coronary arterial vasculopathy. Transplant Proc. 49(1):130–134

41. Luc GY, Choi JH, Rizvi SSA, Pian K, Escriva EM, Patel S et al (2018) Percutaneous coronary intervention versus coronary artery bypass grafting in heart transplant recipients with coronary allograft vasculopathy: a systematic review and meta-analysis of 1,520 patients. Ann Cardiothorac Surg. 7(1):19–30

42. Potena L, Pellegrini C, Franceschi G, Amarelli C, Livio U, Maccherini M et al (2018) Optimizing the safety profile of everolimus by delayed initiation in de novo heart transplant recipients: results of the prospective randomized study EVERHEART. Transplantation. 102(3):493–501

43. Caforio ALP, Tona F, Fortiana AB, Angelini A, Piaserico S, Gambino A et al (2004) Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factors analysis and role of immunosuppression. Am J Transplant. 4(6):962–970

44. Jaffery Z, Prasad A, Lee JH, White CJ (2011) Drug-eluting coronary stents – focus on improved patient outcomes. Patient Rel Outcome Meas. 2:161–174

45. Guaillini G, Shimamura K, Sirbu V, Garbo R, Bocuzzi G, Vassileva A et al (2018) Temporal course of vascular healing and neointimal proliferation after implantation of durable- or biodegradable-polymer drug-eluting stents. Eur Heart J. 39:2448–2456

46. Lee DH, de la Torre Hernandez JM (2018) The newest generation of drug-eluting stents and beyond. Eur Cardiol. 13(1):54–59

47. Wiemer M, Stoilovic S, Samoli A, Dimitriades Z, Ruiz-Nodar JM, Birkemeyer R et al (2017) Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up. Cardiovasc Diabetol. 16:23

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.